KR20240024936A - 혈당 조절 및 체중 관리에 사용하기 위한 인크레틴 유사체를 포함하는 제약 조성물 - Google Patents

혈당 조절 및 체중 관리에 사용하기 위한 인크레틴 유사체를 포함하는 제약 조성물 Download PDF

Info

Publication number
KR20240024936A
KR20240024936A KR1020247002023A KR20247002023A KR20240024936A KR 20240024936 A KR20240024936 A KR 20240024936A KR 1020247002023 A KR1020247002023 A KR 1020247002023A KR 20247002023 A KR20247002023 A KR 20247002023A KR 20240024936 A KR20240024936 A KR 20240024936A
Authority
KR
South Korea
Prior art keywords
weekly dose
dose
weekly
ggg
tri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247002023A
Other languages
English (en)
Korean (ko)
Inventor
테이머 코스쿤
즈본코 밀리세빅
슈웨타 우르바
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20240024936A publication Critical patent/KR20240024936A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020247002023A 2021-06-23 2022-06-22 혈당 조절 및 체중 관리에 사용하기 위한 인크레틴 유사체를 포함하는 제약 조성물 Ceased KR20240024936A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213956P 2021-06-23 2021-06-23
US63/213,956 2021-06-23
PCT/US2022/034437 WO2022271767A1 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management

Publications (1)

Publication Number Publication Date
KR20240024936A true KR20240024936A (ko) 2024-02-26

Family

ID=82608370

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002023A Ceased KR20240024936A (ko) 2021-06-23 2022-06-22 혈당 조절 및 체중 관리에 사용하기 위한 인크레틴 유사체를 포함하는 제약 조성물

Country Status (11)

Country Link
US (3) US12496329B2 (https=)
EP (1) EP4358994A1 (https=)
JP (1) JP2024524180A (https=)
KR (1) KR20240024936A (https=)
CN (1) CN117915939A (https=)
AU (2) AU2022298662B2 (https=)
BR (1) BR112023027321A2 (https=)
CA (1) CA3223313A1 (https=)
IL (1) IL309604A (https=)
MX (3) MX2024000213A (https=)
WO (1) WO2022271767A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102812908B1 (ko) * 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
CN117320740A (zh) * 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548275T3 (es) 2010-03-01 2015-10-15 Eli Lilly And Company Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble
KR102589234B1 (ko) 2017-11-21 2023-10-16 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
AR113486A1 (es) 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途

Also Published As

Publication number Publication date
JP2024524180A (ja) 2024-07-05
US20260091088A1 (en) 2026-04-02
US20240325498A1 (en) 2024-10-03
EP4358994A1 (en) 2024-05-01
AU2022298662A1 (en) 2024-01-18
CN117915939A (zh) 2024-04-19
IL309604A (en) 2024-02-01
AU2025220848A1 (en) 2025-09-11
US20260091087A1 (en) 2026-04-02
MX2024000213A (es) 2024-04-16
MX2025012714A (es) 2025-11-03
AU2022298662B2 (en) 2025-06-05
BR112023027321A2 (pt) 2024-03-12
US12496329B2 (en) 2025-12-16
MX2025012713A (es) 2025-11-03
WO2022271767A1 (en) 2022-12-29
CA3223313A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
Zinman et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+ TZD)
JP5832439B2 (ja) Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
KR20240024936A (ko) 혈당 조절 및 체중 관리에 사용하기 위한 인크레틴 유사체를 포함하는 제약 조성물
KR20200037358A (ko) 지방간 질환 및 지방간염의 치료에서의 glp-1/글루카곤 수용체 작용제
AU2022246002B2 (en) Incretin analog-containing compositions and uses thereof
WO2024006662A1 (en) Tirzepatide compositions and use
KR20240027053A (ko) 마즈두타이드의 용도
JP2025143298A (ja) 糖尿病を治療する方法
Cabré et al. From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
WO2025232124A1 (en) Pharmaceutical compositions and their uses, and methods for improving the storage stability of pharmaceutical compositions
KR20070029276A (ko) 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
JP7803868B2 (ja) 速効型インスリンアナログを含む組成物
EA053233B1 (ru) Способы применения и композиции, включающие аналог инкретина
BR122025000167A2 (pt) Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo
WO2023235724A1 (en) Methods of using a gcg/glp1 co-agonist for therapy
EA050178B1 (ru) Способы лечения диабета
Schliess Insulin glulisine: preclinical hallmarks and clinical efficacy

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000